

**PRELIMINARY AMENDMENT
CONTINUATION APPLICATION OF 09/670,582**

on the nucleotide sequence of hPGIS141. Using these primers and hPGIS141 as a template, a middle stream region of human PGIS cDNA was amplified by PCR method, cleaved with restriction enzymes NspI and PstI, purified and confirmed for the nucleotide sequence and used as NspI-PstI fragment. These Sall-NspI fragment, PstI-BamHI fragment and NspI-PstI fragment were bound and introduced into the Sall-BamHI site of pBluescriptII SK+ (manufactured by STRATAGENE) previously treated with Sall-BamHI, whereby a plasmid (pHPGIS1) containing the whole length human PGIS cDNA was prepared. Fig. 4 shows the restriction enzyme map of pHGPI 1.

**Delete pages 35-51 of the specification, substituting therefor the enclosed
“SEQUENCE LISTING”, pages 35-50, and renumber current pages 52-54 as pages 51-53.**

IN THE CLAIMS:

Please cancel claims 1-20 without prejudice or disclaimer.

Please add the following new claims 21-32:

21. (New) A method for producing an antibody against a human-originated prostacyclin synthase, which comprises using, as an immunogen, a polypeptide comprising an isolated or purified whole or part having immunological activity of an amino acid sequence of a human-originated prostacyclin synthase substantially depicted in the Sequence Listing, Sequence No. 15.

PRELIMINARY AMENDMENT
CONTINUATION APPLICATION OF 09/670,582

22. (New) The method according to claim 21, wherein the polypeptide comprises an amino acid sequence of a human-originated prostacyclin synthase as depicted in the Sequence Listing, Sequence No. 15.

23. (New) The method according to claim 21, wherein the obtained antibody shows the following properties (1) and (2):

- (1) being reactive with a human-originated prostacyclin synthase
- (2) being unreactive with a bovine-originated prostacyclin synthase.

24. (New) The method according to claim 21, wherein the obtained antibody specifically reacts with a human-originated prostacyclin synthase alone.

25. (New) An antibody specific to human prostacyclin synthase produced by using, as an immunogen, a polypeptide comprising an isolated or purified whole or part having immunological activity of an amino acid sequence of a human prostacyclin synthase substantially depicted in SEQ ID NO: 15

26. (New) The antibody according to claim 25, which is a monoclonal antibody.

27. (New) The antibody according to claim 26, which is a purified IgG fraction

28. The antibody according to claim 25, which is a polyclonal antibody.

29. (New) An antibody according to claim 25, wherein the polypeptide comprises an amino acid sequence of a human prostacyclin synthase as depicted in SEQ ID NO:15.

30. (New) The antibody according to claim 29, which is a monoclonal antibody.

**PRELIMINARY AMENDMENT
CONTINUATION APPLICATION OF 09/670,582**

31. (New) The antibody according to claim 30, which is a purified IgG fraction.
32. (New) The antibody according to claim 29, which is a polyclonal antibody.

IN THE ABSTRACT:

**Please delete the present Abstract of the Disclosure and replace it with the following
new Abstract of the Disclosure.**